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Antibiotic susceptibility profiles of selected bacteria cultured 
from the blood of patients in private hospitals in five South 
African centres by various private sector microbiology 
laboratories over a 6-month period in 2006 are described in this 
issue of SAMJ.1 This is the first published study of this nature 
from private sector microbiologists who are members of the 
National Antimicrobial Surveillance Forum (NASF), and it is to 
be hoped that it marks the start of an ongoing process.
The NASF was formed in 2003, through a merger of the 
academic/public sector Antibiotic Study Group (ASG) and 
the private sector Antibiotic Surveillance Forum (ASF).  Its 
mission is to disseminate information on antimicrobial agents, 
including the promotion of reliable antibiotic susceptibility 
testing and documentation of susceptibility patterns in 
clinically relevant pathogens.
Only selected bacteria and limited antimicrobial agents are 
included in the study.  The former include Escherichia coli, 
Klebsiella pneumoniae, Enterobacter spp., Pseudomonas aeruginosa, 
Acinetobacter baumanii and Staphylococcus aureus.  These were 
chosen because they represent the most common hospital-
acquired pathogens and are those in which antibiotic resistance 
is a recognised problem.  However, their ranking among the 
total blood culture isolates during the study period is not 
stated.
Some shortcomings are evident. These include lack of 
standardisation of methodology, no mention of measures to 
exclude repeat isolates, and no distinction between hospital-
acquired and community-acquired isolates. Notably, the extent 
and patterns of resistance to multiple antibiotics among the 
pathogens are not addressed. However, these limitations 
should not detract from the main and important messages 
that come from this study, which are the high levels of 
resistance to key ‘workhorse’ antibiotics used in hospitals, the 
identification of significant prevalences of extended-spectrum 
β-lactamases (ESBLs) and other resistance mechanisms in the 
Enterobacteriaceae studied, and the considerable differences in 
resistance prevalences between centres.
Bacterial resistance to antimicrobial agents – both in 
community and health care settings – has long been recognised 
as a worldwide phenomenon of increasing extent and 
relevance.2 Acquired resistance (resistance emerging in bacterial 
species formerly sensitive to the particular agent/s) is also 
recognised as a consequence of selective pressure in the form of 
antibiotic usage. (It comes as no surprise that in the European 
Union, countries with the lowest overall rates of resistance 
are those with the lowest per capita usage of antibiotics.)  
However, many other factors appear to influence both the rate 
of development and the extent of spread of resistant bacteria. 
In respect of the latter, measures to control cross-infection are 
highly important, particularly in the hospital context.
As noted by the authors, among the Gram-negative bacilli 
studied, the production of broad-spectrum β-lactamases is 
clearly a problem in all centres.  Being mutant derivatives of 
narrower spectrum plasmid-mediated β-lactamases, ESBLs 
have generally remained susceptible to β-lactamase inhibitors 
such as clavulanate and tazobactam – a feature that has 
contributed greatly to their laboratory recognition and some 
clinical role for agents such as co-amoxyclav and piperacillin-
tazobactam.  Recently, however, inhibitor-resistant ESBLs have 
been described, seriously underlining the unwelcome capacity 
of bacteria to keep ahead of man’s efforts in the resistance race.
In addition to these typically plasmid-coded β-lactamases, 
several Enterobacteriaceae, notably Enterobacter spp., produce 
chromosomally coded β-lactamases, mostly of the AmpC 
class.  When first identified AmpC production was an 
inducible phenomenon, the β-lactamase only being produced 
on exposure to the β-lactam agent – some being more 
powerful inducers than others.  Subsequently, in the face of 
such therapy, some isolates mutated to escape the repressor 
mechanism to become constitutive high-level β-lactamase 
producers – sharing high-level resistance to a range of 
penicillins and cephalosporins, including β-lactamase inhibitor 
combinations.  Only cefepime and the carbapenems withstand 
inactivation by these enzymes.  In addition, AmpC-producers 
may acquire mobile plasmid-mediated ESBL production, 
leaving carbapenems (imipenem, meropenem, ertapenem) as 
the only active β-lactams.  These strains are also invariably 
multiresistant to other antibiotics, including aminoglycosides 
and, increasingly, fluoroquinolones.
What are the implications of such resistance in hospital 
clinical practice?  Some of the therapeutic implications are 
discussed by the authors.  Multiple resistance seriously limits 
the range of antimicrobial agents available for treatment of 
infections.  In hospital-acquired infections, inappropriate initial 
antimicrobial therapy is an important determinant of morbidity 
and mortality.3,4 Inappropriateness is usually related to bacterial 
resistance to the prescribed antimicrobial agent(s), although 
other variables such as dosing and route of administration 
may also be relevant.4 Initial empirical choice is best guided by 
contemporary susceptibility data at institutional or preferably 
service and unit (e.g. intensive care unit) level.4
Concerns regarding the adverse impact of such routine 
broad-spectrum initial empirical therapy are real.  Measures 
to reduce this include de-escalation to narrower spectrum 
therapy as early as possible, based on culture results from 
representative specimens collected before initiation of therapy, 
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and shorter courses of therapy.4-6 The role of so-called antibiotic 
rotation or cycling appears unproven to date.5,7
The above require ongoing documentation of significant 
bacterial isolates and their susceptibility to a range of 
potentially applicable antibiotics.  Distinction should also be 
made between hospital-acquired and community-acquired 
isolates.  Appropriate communication of and response to such 
data should be provided for.  Implicit is a requirement for 
appropriate microbiological investigations on representative 
clinical specimens, collected before initiation of antimicrobial 
therapy.
Bantar and co-workers suggest that the value of such 
laboratory-based surveillance data in guiding therapy can 
be enhanced with clinical input to assess the relative roles of 
contamination and true infection.8  As noted in the NASF study, 
methods for susceptibility testing should be standardised, 
thereby improving inter-laboratory comparisons.  Consistent 
methodology will enhance the value of microbiology data at 
local level.  Most microbiology laboratories utilise standardised 
susceptibility testing methods such as those provided by the 
Clinical and Laboratory Standards Institute (CLSI) or the 
British Society for Antimicrobial Chemotherapy (BSAC).9,10 
Nevertheless, it is sobering that optimal susceptibility 
testing for some agents and resistance mechanisms are still 
under investigation.11,12 Given the advent of ‘new’ resistance 
mechanisms and, to a much lesser extent, new antimicrobial 
agents, susceptibility testing promises to be a continually 
evolving area in which standardisation, quality control and 
accreditation will be increasingly important.
Examples of other initiatives to promote prudent antibiotic 
prescribing towards control of antibiotic resistance include 
computerised systems to support decision-making and the 
appointment of dedicated personnel (usually pharmacy-based) 
to monitor and review antibiotic prescribing and to facilitate 
interaction between pharmacy, microbiology and clinical 
personnel.5,13,14
This initial report from the NASF should be applauded.  
Going forward, their challenge will be to make such data 
available on a regular basis, in more centres, to individual 
hospitals, and in some instances to specific departments and 
units (e.g. ICUs).  Their data expose the problem of antibiotic 
resistance but also provide a basis for ongoing surveillance, 
which could underpin the promotion of more effective and 
judicious use of antibiotics in private hospitals.  If the various 
private microbiologists can collaborate to provide these 
data, it is to be hoped that the private hospital networks will 
respond with the will and allocation of resources to utilise this 
information effectively.
Jan van den Ende
Clinical Pathologist
Drs Martin & Sim Inc./Toga Laboratories
Johannesburg
Corresponding author: J van den Ende (jan@togalab.co.za)
  1. Brink A, Moolman J, Cruz da Silva M, Botha M, and the National Antibiotic Surveillance 
Forum. Antimicrobial susceptibility profile of selected bacteraemic pathogens from private 
institutions in South Africa. S Afr Med J 2007, 97: 273-279 (this issue).
  2. Opal SM, Medeiros GM. Molecular mechanisms of antibiotic resistance in bacteria. 
In: Mandell GL, Bennett JE, Dolin R, eds. Principles and Practice of Infectious Diseases. 
Philadelphia: Elsevier, 2005: 253-270.  
  3. Kollef MH. Inadequate antimicrobial treatment: an important outcome for hospitalized  
patient. Clin Infect Dis 2000; 31: suppl 4, S131-138.
  4. Kollef MH. Appropriate empirical antibacterial for nosocomial infections (Getting it right the 
first time). Drugs 2003; 63 (20): 2157-2168.
  5. Paterson DL, Rice LB. Empirical antibiotic choice for the seriously ill patient: Are 
minimizations of selection of selection of resistant organisms and maximisation of individual 
outcome mutually exclusive? Clin Infect Dis 2003; 36: 1006-1012.
  6. Niederman MS. De-escalation therapy in ventilator-associated pneumonia. Curr Opin Crit 
Care 2006; 12: 452-457.
  7. Brown EM, Nathwani D. Antibiotic cycling or rotation; a systematic review of the evidence of 
efficacy. J Antimicrob Chemother 2005; 55: 5-9.
  8. Bantar C, Alcazar G, Franco D, et al. Are laboratory-based antibiograms reliable to guide 
selection of empirical antimicrobial treatment in patients with hospital-acquired infections? J 
Antimicrob Chemother 2007; 59: 140-143.
  9. Performance Standards for Antimicrobial Susceptibility Testing: Seventeenth Informational 
supplement M100-S17. Wayne, PA: Clinical and Laboratory  Standards Institute, 2007.
10. www.bsac.org.uk/susceptibility_testing.cfm (accessed 23 February 2007).
11.  Charlesworth E, Warner M, Livermore DM, et al. Comparison of four methods for teicoplanin 
resistance in methicillin-resistant Staphylococcus aureus. J Antimicrob Chemother 2006; 58: 186-
189.
12.  Hope R, Potz NAC, Warner M, et al. Efficacy of practiced screening methods for detection of 
cephalosporin-resistant Enterbacteriaceae. J Antimicrob Chemother 2007; 59: 110-113.
13. Davey P. The potential role of computerised decision support systems to improve empirical 
antibiotic prescribing. J Antimicrob Chemother 2006; 58: 1105-1106.
14. Wickens HJ, Jacklin A. Impact of the Hospital Pharmacy Initiative for promoting prudent use 
of antibiotics in hospitals in England. J Antimicrob Chemother 2006; 58: 1230-1237.
EDITORIAL
Pg 264-266.indd   266 3/16/07   10:35:18 AM
